Influenza prevention and treatment in transplant recipients and immunocompromised hosts

Influenza and other Respiratory Viruses

Volumn 7, Issue SUPPL.3, 2013, Pages 60-66

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Influenza; M2 inhibitors; Neuraminidase inhibitors; Prevention; Transplantation; Treatment

Indexed keywords

AMANTADINE; DAS 181; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; PLACEBO; RIBAVIRIN; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ADJUVANT THERAPY; ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; DONOR; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA;

INFLUENZA; M2 INHIBITORS; NEURAMINIDASE INHIBITORS; PREVENTION; TRANSPLANTATION; TREATMENT;

ANTIVIRAL AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA, HUMAN;

EID: 84887526642     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12170     Document Type: Review

References (90)

1. Ison MG, Hirsch HH. Influenza: a recurrent challenge to transplantation. Transpl Infect Dis 2010; 12:95-97.
2. Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr Opin infect Dis 2010; 23:365-373.
3. Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-526.
4. Ljungman P, de la Camara R, Perez-Bercoff L et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011; 96:1231-1235.
5. Ng BJ, Glanville AR, Snell G et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant 2011; 11:568-574.
6. Kumar D, Blumberg EA, Danziger-Isakov L et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11:2020-2030.
7. Ison MG, Szakaly P, Shapira MY, Krivan G, Nist A, Dutkowski R. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 2012; 17:955-964.
8. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011; 1:563-573.
9. Kumar D, Morris MI, Kotton CN, Practice ASTIDCo et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10:18-25.
10. Milano F, Campbell AP, Guthrie KA et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood 2010; 115:2088-2094.
11. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-1306.
12. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010; 115:1331-1342.
13. Chakrabarti S, Collingham KE, Marshall T et al. Respiratory virus infections in adult T cell-depleted transplant recipients: the role of cellular immunity. Transplantation 2001; 72:1460-1463.
14. Kumar D, Husain S, Chen MH et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89:1028-1033.
15. Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008; 27:282-288.
16. Peck AJ, Englund JA, Kuypers J et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007; 110:1681-1688.
17. Chien JW, Martin PJ, Gooley TA et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168:208-214.
18. Erard V, Chien JW, Kim HW et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis 2006; 193:1619-1625.
19. Gottlieb J, Schulz TF, Welte T et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009; 87:1530-1537.
20. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11:1071-1078.
21. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L, Boeckh M. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011; 117:5050-5056.
22. Centers for Disease C, Prevention. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613-618.
23. Zaia J, Baden L, Boeckh MJ, Center for International B, Marrow Transplant R, National Marrow Donor P et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44:471-482.
24. Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingham I, the ImmunoCompromised Study G, Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 2012; 206:1250-1259.
25. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008; 42:637-641.
26. Machado CM, Cardoso MR, da Rocha IF, Boas LS, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 2005; 36:897-900.
27. Birdwell KA, Ikizler MR, Sannella EC et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study. Am J Kidney Dis 2009; 54:112-121.
28. Baluch A, Humar A, Egli A et al. Long term immune responses to pandemic influenza A/H1N1 infection in solid organ transplant recipients. PLoS ONE 2011; 6:e28627.
29. Chon WJ, Kadambi PV, Harland RC et al. Changing attitudes toward influenza vaccination in U.S. Kidney transplant programs over the past decade. Clin J Am Soc Nephrol 2010; 5:1637-1641.
30. Magnani G, Falchetti E, Pollini G et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005; 24:588-592.
31. Manuel O, Humar A, Berutto C et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant 2011; 30:679-684.
32. Morelon E, Pouteil Noble C, Daoud S et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 2010; 28:6885-6890.
33. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000; 61:85-93.
34. Broeders NE, Hombrouck A, Lemy A et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol 2011; 6:2573-2578.
35. Esposito S, Meregalli E, Daleno C et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011; 26:2018-2024.
36. Fairhead T, Hendren E, Tinckam K et al. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. Transpl Infect Dis 2012; 14:575-583.
37. Manuel O, Pascual M, Hoschler K et al. Humoral response to the influenza A H1N 1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248-256.
38. Meyer S, Adam M, Schweiger B et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011; 91:1031-1035.
39. Schaffer SA, Husain S, Delgado DH, Kavanaugh L, Ross HJ. Impact of adjuvanted H1N1 vaccine on cell-mediated rejection in heart transplant recipients. Am J Transplant 2011; 11:2751-2754.
40. Siegrist CA, Ambrosioni J, Bel M et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther 2012; 17:893-903.
41. Ison MG, Michaels MG, Practice ASTIDCo. RNA respiratory viral infections in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4):S166-S172.
42. Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect Dis 2013; 15:219-232.
43. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-1373.
44. Vu D, Peck AJ, Nichols WG et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007; 45:187-193.
45. Chen LF, Dailey NJ, Rao AK et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 2011; 203:838-846.
46. Moore C, Galiano M, Lackenby A et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2011; 203:18-24.
47. Ison MG, de Jong MD, Gilligan KJ et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654-1662.
48. Khanna N, Steffen I, Studt JD et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11:100-105.
49. Protheroe RE, Kirkland KE, Pearce RM et al. The clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation Study. Bone Marrow Transplant 2012; 47:88-94.
50. Hurt AC, Chotpitayasunondh T, Cox NJ et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:240-248.
51. Iioka F, Sada R, Maesako Y, Nakamura F, Ohno H. Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation. Int J Hematol 2012; 96:364-369.
52. Tramontana AR, George B, Hurt AC et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16:1068-1075.
53. Shetty AK, Ross GA, Pranikoff T et al. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplant 2012; 16:E153-E157.
54. Speers DJ, Williams SH, Pinder M, Moody HR, Hurt AC, Smith DW. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust 2010; 192:166-168.
55. Seo S, Englund JA, Nguyen JT et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 2013; 18:377-386.
56. Boudreault AA, Xie H, Leisenring W, Englund J, Corey L, Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant 2011; 17:979-986.
57. Cost C, Brock E, Adams-Huet B, Siegel JD, Ardura MI. 2009 pandemic influenza A (H1N1) virus infection in pediatric oncology and hematopoietic stem cell transplantation patients. Pediatr Blood Cancer 2011; 56:127-133.
58. George B, Ferguson P, Kerridge I, Gilroy N, Gottlieb D, Hertzberg M. The clinical impact of infection with swine flu (H1N109) strain of influenza virus in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2011; 17:147-153.
59. Mohty B, Thomas Y, Vukicevic M et al. Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47:236-242.
60. Rihani R, Hayajneh W, Sultan I et al. Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 2011; 46:1430-1436.
61. Fox BD, Raviv Y, Rozengarten D, Rusanov V, Bakal I, Kramer MR. Pandemic influenza (H1N1): impact on lung transplant recipients and candidates. J Heart Lung Transplant 2010; 29:1034-1038.
62. Gainer SM, Patel SJ, Seethamraju H, Moore LW, Knight RJ, Gaber AO. Increased mortality of solid organ transplant recipients with H1N1 infection: a single center experience. Clin Transplant 2012; 26:229-237.
63. Smud A, Nagel CB, Madsen E et al. Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study. Transplantation 2010; 90:1458-1462.
64. Johny AA, Clark A, Price N, Carrington D, Oakhill A, Marks DI. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 29:113-115.
65. Medeiros R, Rameix-Welti MA, Lorin V et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther 2007; 12:571-576.
66. Dohna-Schwake C, Schweiger B, Felderhoff-Muser U et al. Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications. Transplantation 2010; 90:223-224.
67. Ghosh S, Adams O, Schuster FR, Borkhardt A, Meisel R. Efficient control of pandemic 2009 H1N1 virus infection with intravenous zanamivir despite the lack of immune function. Transpl Infect Dis 2012; 14:657-659.
68. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:1381-1382.
69. van der Vries E, Collins PJ, Vachieri SG et al. H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog 2012; 8:e1002914.
70. Campbell AP, Jacob ST, Kuypers J et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med 2010; 152:619-620.
71. Renaud C, Pergam SA, Polyak C et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010; 12:513-517.
72. Shetty AK, Peek LA. Peramivir for the treatment of influenza. Expert Rev Anti Infect Ther 2012; 10:123-143.
73. Hoopes JD, Driebe EM, Kelley E et al. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus. PLoS ONE 2011; 6:e29778.
74. Fraaij PL, van der Vries E, Beersma MF et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011; 204:777-782.
75. Carrat F, Duval X, Tubach F et al. Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households. Antivir Ther 2012; 17:1085-1090.
76. Duval X, van der Werf S, Blanchon T et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7:e1000362.
77. Hayden FG. Experimental human influenza: observations from studies of influenza antivirals. Antivir Ther 2012; 17:133-141.
78. Drozd DR, Limaye AP, Moss RB et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis 2013; 15:E28-E32.
79. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis 2012; 206:1844-1851.
80. Guzman-Suarez BB, Buckley MW, Gilmore ET et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transpl Infect Dis 2012; 14:427-433.
81. Chen YB, Driscoll JP, McAfee SL et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis 2011; 53:e77-e80.
82. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011; 11:1123-1130.
83. Likos AM, Kelvin DJ, Cameron CM, Rowe T, Kuehnert MJ, Norris PJ, National Heart LBIREDS, II. Influenza viremia and the potential for blood-borne transmission. Transfusion 2007; 47:1080-1088.
84. Sobata R, Matsumoto C, Igarashi M et al. No viremia of pandemic (H1N1) 2009 was demonstrated in blood donors who had donated blood during the probable incubation period. Transfusion 2011; 51:1949-1956.
85. Stramer SL, Collins C, Nugent T et al. Sensitive detection assays for influenza RNA do not reveal viremia in us blood donors. J Infect Dis 2012; 205:886-894.
86. Cockbain AJ, Jacob M, Ecuyer C, Hostert L, Ahmad N. Transplantation of solid organs procured from influenza A H1N1 infected donors. Transpl Int 2011; 24:e107-e110.
87. Halliday N, Wilmore S, Griffiths PD, Neuberger J, Thorburn D. Risk of transmission of H1N1 influenza by solid organ transplantation in the United Kingdom. Transplantation 2012; 93:551-554.
88. Le Page AK, Kainer G, Glanville AR, Tu E, Bhonagiri D, Rawlinson WD. Influenza B virus transmission in recipients of kidney and lung transplants from an infected donor. Transplantation 2010; 90:99-102.
89. Meylan PR, Aubert JD, Kaiser L. Influenza transmission to recipient through lung transplantation. Transpl Infect Dis 2007; 9:55-57.
90. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J 2001; 18:971-976.